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Abstract
Background: Schistosomiasis is a parasitic disease infecting more than 200 million people in the world. Although
chemotherapy targeting on killing schistosomes is one of the main strategies in the disease control, there are few effective
ways of dealing with liver fibrosis caused by the parasite infection in the chronic and advanced stages of schistosomiasis.
For this reason, new strategies and prospective drugs, which exert antifibrotic effects, are urgently required.
Methods and Findings: The antifibrotic effects of praziquantel were assessed in the murine models of schistosomiasis
japonica. Murine fibrosis models were established by cutaneous infection with 1462 Schistosoma japonicum cercariae.
Then, the mice of both chronic (8 weeks post-infection) and advanced (15 weeks post-infection) schistosomiasis were
treated by gavage of praziquantel (250 mg/kg, once daily for 3 days) to eliminate worms, and followed by praziquantel anti-
fibrosis treatment (300 mg/kg, twice daily for 30 days). The fibrosis-related parameters assessed were areas of collagen
deposition, content of hydroxyproline and mRNA expressions of Col1a1, Col3a1, a-SMA, TGF-b, MMP9, TIMP1, IL-4, IL-10, IL-
13 and IFN-c of liver. Spleen weight index, alanine aminotransferase activity and liver portal venous pressure were also
measured. The results showed that anti-fibrosis treatment improved liver fibrosis, splenomegaly, hepatic function, as well as
liver portal hypertension. In order to confirm the anti-fibrotic properties of praziquantel, we established a CCL4-induced
model and revealed that CCL4-induced liver fibrosis was inhibited by PZQ treatment for 30 days. Furthermore, we analyzed
the effects of praziquantel on mouse primary hepatic stellate cells (HSCs). It is indicated that mRNA expressions of Col1a1,
Col3a1, a-SMA, TGF-b, MMP9 and TIMP1 of HSCs were all inhibited after praziquantel anti-parasite treatments.
Conclusions: The significant amelioration of hepatic fibrosis by praziquantel treatment validates it as a promising drug of
anti-fibrosis and offers potential of a new chemotherapy for hepatic fibrosis resulting from schistosomiasis.
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Introduction
Schistosomiasis is a tropical parasitic disease caused by blood-
dwelling fluke, schistosome. According to WHO, 200 million
people are infected by the parasite worldwide, leading to the loss of
1.53 million disability-adjusted life years [1]. The main pathologic
lesions of hepatic schistosomiasis are the granuloma formation
around schistosome eggs at acute stage of the infection, followed
by the liver fibrosis at chronic and advanced stages [2]. Hepatic
fibrosis of schistosomiasis results from a massive deposition of
extracellular matrix (ECM) in the periportal spaces, leading to
blockage of the portal veins, portal hypertension, splenomegaly,
portocaval shunting, and gastrointestinal varices [1]. The
persistent fibrosis of chronic schistosomiasis may cause hepatic
cirrhosis and high mortality rate for liver cancer [3]. Although
chemotherapy eliminates matured worms effectively and prevents
the accumulation of schistosome eggs, less effective durgs are
direct to reverse the existing hepatic fibrosis, especially at chronic
and advanced stages of schistosomiasis. Therefore, treatment
targeting hepatic fibrosis of schistosomiasis remains a challenging
proposition [4].
Hepatic stellate cells(HSCs) are considered as an important liver
resident cells, which are the major cellular sources of extracellular
matrix (ECM) and play a key role in the process of hepatic fibrosis
[5,6]. Deposition of collagen, imbalance of matrix metalloprotei-
nase (MMP)/tissue inhibitor of metalloproteinase(TIMP) and
secretion of profibrotic cytokines caused by activated HSCs are
described previously in schistosomiasis and other infectious
diseases [7,8]. According to their pivotal role, HSCs have been
recognized as the therapeutic targets of hepatic fibrosis caused by
permanent alcohol abuse [9], nonalcoholic steatohepatitis [10],
Hepatitis C [11] and schistosomiasis [12].
Praziquantel (PZQ), as a safe anti-schistosome drug, has been
used for more than 30 years [13]. It has been documented that
PZQ has only mild side-effect and very low toxicity in animals
[14]. No important long term safety problems have been observed
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20247in people and the safety is also considered in both children and
pregnant women [15]. Reversal of schistosome-induced pathology
after treatment of PZQ has been described. Parasitological cure of
murine Schistosoma monsoni infection was followed by eventual
partial reversal of liver fibrosis [16]. Researchers showed that
patients in Ethiopia and Uganda had improvement or resolution
Figure 1. Anti-fibrosis treatment with prizaquantel reduced areas of liver Sirius Red staining and liver hydroxyproline contents of
mice 8 weeks post infection with Schistosoma japonicum. (A) Representative images of Sirius Red staining by light microscope (6100). Ai,
uninfected; Aii, infected; Aiii, anti-parasite; Aiv, anti-fibrosis. (B) Statistical analysis of scanned images in Sirius Red staining by software IPP6.0. (C)
Measurement of liver hydroxyproline content. (* p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0020247.g001
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cure of PZQ [17,18]. The main explanations of these results are
presumed to be probably a removal of schistosomal worms and
subsequent reduction of egg deposition. However, the exact
mechanism is not clear.
Recent years, in addition to anti-helminth effect, anti-
inflammation of PZQ has been reported [19]. Report also
showed that eight- weeks- continuing treatment with PZQ could
inhibit the development of pulmonary granulomas caused by vein
injection of Schistosoma japonicum (S. japonicum) eggs, suggesting that
PZQ may have the effect on fibrosis [20]. It seems that PZQ may
not only eliminate the parasites, but also influence the immune
response of the host, and consequently exerts dual effects on the
infection. The aim of our study is to investigate whether PZQ has
Figure 2. Anti-fibrosis treatment with prizaquantel reduced spleen weights in mice 8 weeks post infection with Schistosoma
japonicum. (A) images of representative spleens in different groups. The bar is 1 cm. (B) Statistical analysis of spleen weights. (C) Spleen weight index
(spleen weight/body weight). (* p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0020247.g002
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japonica and prospect it as a well tolerated, easily administered
and inexpensive drug for new treatment strategy of hepatic
schistosomiasis.
Materials and Methods
Animals and drug
Female BABL/c mice (Comparative Medicine Center of
Yangzhou University, Yangzhou, China), 6–8 weeks old, were
used throughout the study and maintained according to guidelines
approved by the Nanjing Medical University Animal Experiment
and Care Committee. S. japonicum cercariae of chinese mainland
strain were obtained from the infected Oncomelania hupensis (Jiangsu
Institute for Schistosomiasis Control, Wuxi, China). PZQ was
purchased from Sigma and resuspanded in 1% carboxymethyl
cellulose carrier for use.
Establishment of infection model and strategy of PZQ
treatment
The BABL/c mice were infected cutaneously with 1462 S.
japonicum cercariae [21].The liver fibrosis models were established
after the mice being infected for 8 weeks and 15 weeks,
respectively. Intragastric administrations of PZQ (250 mg/kg/
24 hours) for 3 days and continuing 1% carboxymethyl cellulose
carrier up to 30 days were carried out as an anti-parasite
intervention [16]. Intragastric administrations of PZQ (300 mg/
kg/12 hours) for one month were carried out as an anti-fibrosis
intervention. Both interventions were carried out for the mice of
eight- weeks-infection and fifteen- weeks-infection, respectively
(n=10 in each group). A low dose administration of PZQ (75 mg/
kg/12 hours) for one month was also used for the mice of fifteen-
weeks-infection (n=10). Concurrent control of untreated mice
(n=10) with liver fibrosis and uninfected mice (n=8) were
intragastric administrations of equal value of carboxymethyl
cellulose carrier. When animals were sacrificed at the last time
of treatment, liver portal venous pressures were measured, and
tissues (livers and spleens) and serum were collected. Perfusions of
hepatic portal system were performed to detect the number of
adult worms as described [22]. For in vivo experiments on primary
mouse HSCs, the mice getting the infection for 12 weeks and then
administrating 250 mg/kg PZQ for 3 days were employed (n=6
in each group).
Sirius Red staining and measure of liver hydroxyproline
content
Mice livers were fixed in 10% neutralized formaldehyde and
embedded in paraffin, and tissue sections (4-mm thick) were stained
with aqueous saturated solution of picric acid containing 0.1%
Sirius Red (Sigma-Aldrich, St. Louis, MO). Images of six random
microscopic fields of red- stained collagen fibers in the liver section
of each mouse were recorded using an inverted microscope
(ZEISS, Goettingen, Germany) and then digitized and analyzed
on Image-Pro Plus software 6.0 as previously described [21]. The
content of liver hydroxyproline was determined according to the
protocol of the Hydroxyproline Testing Kit (Jiancheng, Nanjing,
China) as described [23].
Immunohistochemistry assay for a-SMA of liver
Smooth muscle actin alpha (a-SMA) (Sigma-Aldrich, St. Louis,
MO), a marker of activated HSCs, was detected on formaldehyde-
fixed paraffin-embedded sections by immunohisto- chemistry
method. Images of six random microscopic fields in the sections
of each mouse were recorded using an inverted microscope
(ZEISS, Goettingen, Germany) and the a-SMA positive area of
each image was analyzed by Image-Pro Plus software 6.0 software
[21].
Measurement of mice serum alanine aminotransferase
(ALT) and aspartate aminotransferase(AST)
Mice blood were collected in 1.5 ml Eppendorf tubes and standing
in room temperature for 4 hours. The serums were separated by
centrifugation at 3500 r/min for 15 minutes and serum ALT/AST
was detected by Olympus AU5400 automatic biochemistry analyzer.
Measurement of liver portal venous pressure
Mouse was anesthetized with 2% Pentobarbital Sodium, then
peritoneal cavity was opened and hepatic portal vein was
canulated. Strain gauge transducer was used to get the signal
from liver portal vein and the signal was recorded by Power-
Lab8SP (ADInstruments, Castle Hill, Australia). Data acquisition
was performed using Chart software v5.4 [24].
Isolation and culture of mice primary HSCs
HSCs were isolated from mice by the modified mothed as
described [25]. Mice were anesthetized with 2% Pentobarbital
Sodium. Peritoneal cavity was opened and hepatic portal vein was
canulated. In situ perfusion of the livers was initiated with 40 mL
DMEM (Hyclone, Thermo Fisher Scientific, Beijing, China) and
at the same time the suprahepatic inferior vena cava was cut. The
liver was removed, placed in a dish and perfused continually with
DMED containing 0.04% collagenase type IV and 0.2% pronase
(Gibco Life Technologies, Grand Island, NY, USA) at 37uC for
10 minutes. Then, the liver was further digested with DMEM
containing 0.08% collagenase type IV, 0.08% pronase and 10 U/
ml DNase I (Sigma-Aldrich, St. Louis, MO) at 37uC bath shaking
for 30 minutes. The resulting cell suspension was filtered through
Figure 3. Anti-fibrosis treatment with prizaquantel reduced
serum alanine aminotransferase (ALT) levels in mice 8 weeks
postinfectionwithSchistosoma japonicum. Serum ALT was assessed
by Olympus AU5400 automatic biochemistry analyzer. (* p,0.05,
** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0020247.g003
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percent Optiprep(Axis-Shield PoC AS, Oslo, Norway) was used
for density gradient centrifugation to isolate HSCs [26,27] and
purity of HSCs was estimated based on the autofluorescence of the
cells by ultraviolet-excited fluorescence microscopy. Cell viability
was examined by Trypan blue exclusion. Both cell purity and
viability were in excess of 90% [28].
RNA isolation and Real Time PCR
Tissues or cells were homogenized in Trizol (Invitrogen,
Carlsbad, CA) and their RNAs were extracted according to the
manufacturer’s protocol. The RNA purity was assessed by
spectrophotometry and 2% (w/v) agarose gel electrophoresis.
Reverse transcriptase (RT) reactions for cDNA synthesis were
carried out using RevertAid
TM First Strand cDNA Synthesis Kit
with oligo-dT primer (Fermentas,EU). Relative expression of
mRNA species was determined by Real Time PCR with Faststart
Universal SYBR Green PCR Master(Roche Diagnostics, India-
napolis, IN, USA) using ABI7300. The primers formouse GAPDH
(Forward 59-TGGAAAGCTGTGGCGTGAT-39, Reverse 59-
TGCTTCACCACCTTCTTGAT-39) [29], mouse TGF-b (For-
ward 59-CACCGGAGAGCCCTGGATA-39, Reverse 59-TGTA-
CAGCTGCCGCACACA-39) [30],mouse a-SMA(Forward 59-T-
CAGCGCCTCCAGTTCCT-39, Reverse 59-AAAAAAAACCA-
CGAGTAACAAATCAA-39) [30],mouse Col1a1(Forward 59-A-
CGTCCTGGTGAAGTTGGTC-39, Reverse 59-CAGGGAAG-
CCTCTTTCTCCT-39) [31],mouse Col3a1(Forward 59-TGGT-
CCTCAGGGTGTAAAGG-39, Reverse 59-GTCCAGCATCA-
CCTTTTGGT-39) [32],mouse MMP9(Forward 59-GCTCATG-
TACCCGCTGTATAGCT-39, Reverse 59-CAGATACTGGAT-
GCCGTCTATGTC-39) [33], mouse TIMP1(Forward 59-TGG-
GAAATGCCGCAGATATC-39, Reverse 59-TGGGACTTGT-
GGGCATATCC-39) [33], mouse IL-4(Forward 59-GGTCTC-
AACCCCCAGCTAGT-39, Reverse 59-GCCGATGATCTCT-
CTCAAGTGAT-39), mouse IL-10(Forward 59-GCTCTTACT-
GACTGGCATGAG-39, Reverse 59-CGCAGCTCTAGGAGC-
ATGTG-39), mouse IL-13(Forward 59-CCTGGCTCTTGCT-
TGCCTT-39, Reverse 59-GGTCTTGTGTGATGTTGCTCA-
39) and mouse IFN-c(Forward 59-ATGAACGCTACACACTG-
CATC-39, Reverse 59-CCATCCTTTTGCCAGTTCCTC-39)
were gained from articles orPrimerBank (http://pga.mgh.har-
vard.edu/primerbank/), and used for PCR. Cycling conditions
were 2 min at 50uC, then 10 min at 95uC and followed by 40
cycles of 95uC for 15 s and 60uC for 1 min. Melt curve analysis
and 2% agarose gel electrophoresis of the amplicon were used to
determine the specificity of the amplicon. Data were normalized
with GAPDH and results were expressed as fold amplification
using the method described by Pfaffl [34]. Each experiment was
repeated three times.
Statistics
The data were analyzed using two-tailed Student’s t-test when
compared between two groups. A p-value,0.05 was considered
statistically significant. All statistical analyses were operated by
GraphPad Prism software 5.0.
Results
PZQ Treatment Decreases Liver Fibrosis and Its Related
Gene Expressions in the Mice with Chronic
Schistosomiasis
PZQ was administrated to the mice infected with S. japonicum at
week 8 post-infection for either 3 days (anti-parasite group,
250 mg/kg/day) or 30 days (anti-fibrosis group,300 mg/kg/
12 hours). Homochronous normal mice (uninfected group) and
untreated mice (infected group) were also used in the experiments.
The perfusion of hepatic portal system showed that no adult worm
was detected in anti-parasite group at the end of the treatment
(data not shown), which demonstrated that the administration of
PZQ for anti-parasite treatment resulted in parasitologic cure. As
shown in figures 1A and 1B, the areas of Sirius Red- stained liver
were significantly decreased in anti-fibrosis group in comparison to
both infected group and anti-parasite group. The accordant results
were observed in measurement of liver hydroxyproline contents
(Figure 1C). In addition, the spleen weight and the spleen index
(spleen weight/body weight) of the mice were also reduced in anti-
fibrosis group in comparison to both infected group and anti-
parasite group (Figure 2). Serum ALT which was dramatically
increased after the infection was decreased by anti-fibrosis therapy
of PZQ (Figure 3).
Hepatic mRNA expressions of the genes associated with liver
fibrosis were detected by Real Time PCR. Results showed that the
levels of Col1a1, Col3a1, a-SMA, MMP9 and TIMP1 were
decreased while TGF-b was increased in anti-parasite group in
comparison to infected group and all of them were decreased in
anti-fibrosis group in comparison to both infected group and anti-
parasite group (Figure 4A–F). Immunohistochemistry assay
showed that a-SMA positive cells around the hepatic egg
granulomas were dramatically decreased in anti-fibrosis group in
comparison to both infected group and anti-parasite group
(Figure 4G–H).
Besides, CCL4-induced early and established liver fibrosis mice
[35] was brought into our experiment (Text S1). PZQ treatment
significantly reduced the collagen areas in CCL4-induced fibrotic
liver assessed by Sirius Red staining (Figure S1A–D). Content of
hepatic hydroxyproline (Figure S1E) as well as serum ALT and
AST (Figure S1F) was also decreased significantly in PZQ treated
mice.
PZQ Treatment Decreases Liver Fibrosis and Enhances
MMP9 gene Expression of Mice with Advanced
Schistosomiasis
In this study, PZQ was administrated to the mice infected
with S.japonicum at week 15 post-infection for either 3 days (anti-
parasite group, 250 mg/kg/day) or 30 days (anti-fibrosis low
dose group, 75 mg/kg/12 hours; anti-fibrosis high dose group,
3 0 0m g / k g / 1 2h o u r s ) .H o m o c h r o nous normal mice (uninfected
group) and untreated infected mice (infected group) were also
used in the experiments. As expected, the areas of Sirius Red
staining on the liver sections were significantly decreased in high
d o s eg r o u pi nc o m p a r i s o nt ob o t hi n f e c t e dg r o u pa n da n t i -
Figure 4. Anti-fibrosis treatment with prizaquantel inhibited expressions of liver profibrotic genes and a-SMA protein expression
in mice 8 weeks post infection with Schistosoma japonicum. The expressions of mRNA were detected by Real Time PCR. (A) Expression of a-
SMA. (B) Expression of Col1a1. (C) Expression of Col3a1. (D) Expression of TGF-b. (E) Expression of MMP9. (F) Expression of TIMP1. a-SMA protein
expression was assessed by immunohistochemistry (G) Representative images of immunohistochemistry by light microscope (6100). Gi, uninfected;
Gii, infected; Giii, anti-parasite; Giv, anti-fibrosis. Arrows showed the positive staining. (H) a-SMA positive areas were measured by software IPP6.0.
(* p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0020247.g004
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decreased without statistical significance in comparison to anti-
parasite group. Also, the change profiles of the liver hydroxy-
proline contents were in accordance with those of Sirius Red
staining (Figure 5). The spleen weights of mice in anti-parasite
group and anti-fibrosis groups (both low dose and high dose)
were decreased in comparison to infected group, but no
significant differences between them (Figure 6). Portal hyper-
tension is a characteristic manifestation of advanced schistoso-
miasis japonica and resulted mainly from severe hepatic fibrosis.
To evaluate the anti-fibrosis effects of PZQ on the mice with
advanced schistosomiasis, we measured liver portal venous
pressure. The results showed that the pressure of the mice were
significantly decreased after anti-parasite treatment and further
decreased to nearly normal levels after both low dose and high
dose treatment of PZQ (Figure 7). Serum ALT levels were
significantly decreased only in high dose group, which were
nearly back to normal baselines (Figure 8).
We also detected the expressions of fibrosis-related genes.
Col1a1, Col3a1, a-SMA and TGF-b mRNAs of liver were all
markedly decreased in high dose group in comparison to both
infected group and anti-parasite group (Figure 9A–D), which
were similar to those changes in the mice with chronic
schistosomiasis. Liver TIMP1 mRNA was reduced in low dose
group, but more significantly decreased in high dose group in
comparison to anti-parasite group. However, the expression of
liver MMP9 mRNA was increased nearly five-fold in high dose
group in comparison to both anti-parasite group and low dose
group (Figure 10E–F). Hence, PZQ did not inhibit all kinds of
fibrosis-related genes in liver. The immunohistochemistry
change of liver a-SMA in each group was accordant with its
a-SMA mRNA expression (Figure 9G–H). Gene Expressions of
Th1/Th2 cytokines of IL4, IL10, IL13 and IFN-c were all
reduced in high dose group in comparison to infected, anti-
parasite and low dose group, respectively (Figure 9I–L). Normal
mice treated with high dose PZQ for 30 days (Text S2) showed
reduced mRNA expression of Col1a1, TGF-b and TIMP1 in
liver in comparison to untreated control mice (Figure S2A, D
and F). Col3a1a n da-SMA (Figure S2B and C) showed a
tendency to decrease, while MMP9 (Figure S2E) showed a
tendency to increase, but the changes were not significant
statistically. We also demonstrated that PZQ did not inhibit the
proliferation of splenic mononuclear cells stimulated by schisto-
somal egg antigens detected by incorporation of
3H-thymidine
(TDR) (Text S3 and Figure S3).
PZQ Treatment Inhibits Activation or Fibrosis-related
gene expressions of Primary HSCs in Mice with Chronic
Schistosomiasis
PZQ was administrated to the mice infected with S.japonicum at
week 12 post-infection for 3 days (250 mg/kg/day) and primary
HSCs were isolated for detection of mRNA expression. Consistent
with anti-fibrosis treatment experiment of the mice with chronic
schistosomiasis, the expressions of activation or fibrosis-related
genes such as Col1a1, Col3a1, a-SMA, TGF-b, MMP9 and
TIMP1 were all decreased significantly after the anti-parasite
treatment with PZQ (Figure 10).
Discussion
Although it remain a neglected transmissible disease, affecting
people mainly in developing countries, schistosomiasis are second
only to malaria as a major parasitic disease [36]. So far, although
chemotherapy makes a great success in against all schistosome
species, few admitted and widely used interventions of anti-fibrosis
can be accepted to improve the hepatic fibrosis and treatment of
hepatic fibrosis for the patients with schistosomiasis is neglected all
the while. The patients with severe diseases have no choice but
surgery for enlarged spleens or fibrotic liver to avoid the risk of
death [37,38]. Consequently, radical therapy of hepatic fibrosis
remains an imperative requirement and new effective drugs of
anti-fibrosis are eager to be applied in clinical.
PZQ, as an antihelminthic drug, is widely used now. After PZQ
anti-parasite therapy, hepatic fibrosis is reversal in murine
schistosomiasis model and the reversal is considered due to
pathogenic cure [39]. Other effects have been reported too in
recent years [19,20], suggesting that PZQ may have direct effect
on host. However, there is no report about the direct anti-fibrosis
effect and mechanism of PZQ on liver. In our experiments, we
adopted continuous and therapeutic dose (600 mg/kg/day for
murine approximately converts to 60 mg/kg/day for human [40])
of PZQ for anti-fibrosis treatment and investigated whether it has
Figure 5. Anti-fibrosis treatment with prizaquantel reduced areas of liver Sirius Red staining and liver hydroxyproline content in
mice 15 weeks post infection with Schistosoma japonicum. (A) Representative images of Sirius Red staining by light microscope (6100). Ai,
uninfected; Aii, infected; Aiii, anti-parasite; Aiv, low dose; Av, high dose. (B) Statistical analysis of scanned images in Sirius Red staining by software
IPP6.0. (C) Measurement of Liver hydroxyproline content. (* p,0.05).
doi:10.1371/journal.pone.0020247.g005
Figure 6. Spleen weights were not changed after Anti-fibrosis
treatment with low dose or high dose prizaquantel compared
with anti-parasite treatment in mice 15 weeks post infection
with Schistosoma japonicum. Spleen weights were reduced in anti-
parasite, anti-fibrosis low dose and high dose groups compared with
infected group, but no significant changes were found between treated
groups. (** p,0.01).
doi:10.1371/journal.pone.0020247.g006
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schistosomiasis hepatic fibrosis treatment.
Because mouse model is of high homologization and has similar
course with human schistosomiasis, we thus established the mouse
schistosomiasis model [41]. In the study, we demonstrated that
anti-fibrosis treatment with PZQ significantly improved the
hepatic fibrosis of schistosomiasis japonica at both 8 weeks and
15 weeks post-infection, as measured by Sirius Red staining areas
and hydroxyproline content. We also detected the clinical
parameters, such as spleen weight, portal venous pressure and
serum ALT. The results showed that clinical symptoms, such as
splenomegaly [42,43], portal hypertension [44,45] and dysregu-
lated liver function [46,47] were ameliorated by anti-fibrosis
treatment with PZQ. Low dose treatment with PZQ did not show
significant effects on hepatic fibrosis, which may be due to the
quick metabolism of this drug in liver [48]. Because of the
probable formation of fibrotic spleens [47], the enlarged spleens
were not reversed by treatment of PZQ in advanced schistosomi-
asis mice. Meanwhile, hepatic fibrosis was more serious in 15
weeks- post-infected mice than in 8 weeks- post-infected mice
before and after treatment. Herein, we suggest that anti-fibrosis
treatment with PZQ should be used as early as possible and
delayed treatment will be difficult to reverse the splenomegaly and
hepatic fibrosis.
To further confirm the reversal of hepatic fibrosis, we detected
the transcriptional level of some profibrotic genes in liver, such as
Col1a1 and Col1a3 which are predominant collagens in the liver
of schistosomiasis mice [49,50]. TGF-b is considered as typical
profibrotic gene in the progress of hepatic fibrosis [51,52], and also
plays an important role in hepatic fibrosis of schistosomiasis
[53,54]. The expressions of TGF-b, as well as a-SMA which is the
activated marker of HSCs [7,55], were detected between each
group. All of them were decreased after anti-fibrosis treatment of
PZQ, suggesting that anti-fibrosis treatment of PZQ inhibits
transcriptional levels of profibrotic gene expressions in schistoso-
miasis mouse liver.
Besides, gene expressions of Th1/Th2 cytokines such as IL-4,
IL-10, IL-13 and IFN-c, which were important in schistosomi-
asis liver fibrosis [21,56,57], were also detected in our
experiment. Studies in schistosomiasis demonstrated that the
development of fibrosis requires the production of the profibrotic
cytokines IL-4 and IL-13 [58,59,60]. Oppositely, IL-10 and
IFN-c showed antifibrotic effects [57]. Our results demonstrated
that anti-fibrosis treatment with PZQ significantly inhibited the
gene expression of both Th1 and Th2 cytokines, which
suggested that the alteration of Th1/Th2 cytokines in hepatic
microenvironment after PZQ treatment might finally influence
the resolution of hepatic fibrosis. Furthermore, although
expressions of fibrosis associated genes in liver of normal mice
were low, PZQ treatment could also inhibit the expression of
them such as Col1a1, TGF-b and TIMP1 in our experiment.
Therefore, PZQ treatment could regulate the expression of
fibrosis associated genes not only on schistosomiasis mice but
also on normal mice.
The balance of the activities between matrix metalloproteinases
(MMPs) and TIMPs(tissue inhibitors of metalloproteinases) plays
an important role in extracellular matrix(ECM) production and
degradation in hepatic fibrosis [61,62]. MMP9 with the activity of
collagen degradation [21,63] has multi-source and is produced by
Kupffer cells [64], hepatocytes [65] and HSCs [66]. Meanwhile,
HSCs is also the main source of TIMP1 [8]. In our chronic fibrosis
model, we showed that treatment of anti-fibrosis with PZQ
reduced transcriptional levels of MMP9 and TIMP1. Meanwhile,
TIMP1 was more close to the normal level than MMP-9.
Unexpectedly, we observed a high transcriptional level of
MMP9 by anti-fibrosis treatment with PZQ in liver of advanced
infected mice, whereas TIMP1 was significantly reduced. Thus,
the imbalance that favors MMP9 by PZQ treatment is helpful to
reverse hepatic fibrosis.
Unlike schistosome egg induced hepatic granuloma and fibrosis,
CCL4-induced liver fibrosis is mainly due to the damage of
hepatocyte [35]. However, the mechanism of resulting liver
fibrosis is the same that is the activation of HSCs and subsequent
ECM deposition [5]. In order to confirm the anti-fibrotic
properties of PZQ, we established mice model of CCL4-induced
liver fibrosis. As expected, PZQ treatment significantly reduced
liver collagen areas and hydroxyproline content in mice of CCL4-
induced liver fibrosis. Level of serum ALT and AST were also
significantly reduced after PZQ treatment. These results further
confirmed the anti-fibrosis effects of PZQ.
To further investigate cellular mechanism of anti-fibrosis with
PZQ, we focused on HSCs, which is one of liver resident cells
and plays the key role in liver fibrosis [5,7]. In recent researches,
Figure 8. Anti-fibrosis treatment with prizaquantel reduced
serum alanine aminotransferase (ALT) level in mice 15 weeks
post infection with Schistosoma japonicum. Serum ALT was
assessed by Olympus AU5400 automatic biochemistry analyzer. Levels
of serum ALT were significantly decreased nearly to the normal level
after anti-fibrosis treatment with high dose prizaquantel. (* p,0.05).
doi:10.1371/journal.pone.0020247.g008
Figure 7. Anti-fibrosis treatment with prizaquantel reduced hepatic portal venous pressure. Hepatic portal venous pressure was
measured by PowerLab8SP and analyzed by chart5 software. (A) Representative recording images were showed: Ai, uninfected; Aii, infected; Aiii anti-
parasite; Aiv, low dose; Av, high dose. (B) Statistical analysis of each group hepatic portal venous pressure. Although anti-parasite treatment reduced
portal venous pressure compared with infected group, anti-fibrosis treatment (both low dose and high dose group) further reduced the pressure to
nearly uninfected level. (** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0020247.g007
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PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e20247HSCs is the promising target of anti-fibrosis drugs [67]. In our
experiments with mouse models, we found the reduced
transcriptional levels of the fibrosis-related genes Col1a1,
Col3a1, a-SMA, TGF-b, MMP9 and TIMP1 in primary HSCs
by PZQ treatment for 3 days. This result was consistent with anti-
fibrosis treatment experiment of mice with chronic schistosomi-
asis, indicating that inhibition of HSCs activation by PZQ
occured rapidly after the treatment. More importantly, the
inhibition was persistence and no rebounding of this effect was
observed at the end of anti-parasite treatment. Therefore, PZQ
might exhibit the anti-fibrosis property by affecting activation of
HSCs. Although the appropriate dose-course of anti-fibrosis
treatment by PZQ is not determined and the exact pathway is not
clear, our results suggest that PZQ is a promising drug for the
treatment of hepatic fibrosis.
In conclusion, although the pathways about anti-fibrosis
property of PZQ are enigmatic, we demonstrated the effects of
anti-fibrosis of PZQ in mice with both chronic and advanced
schistosomiasis as well as in CCL4-induced liver fibrosis mice. Our
study also provided clues that based on the changes following PZQ
treatment, the levels of TGF-b and TIMP-1 were potential
biomarkers for regression of liver fibrosis. It is suggested that new
treatment strategy in clinical is that treatment of pathogenic
intervention could be adopted at first and followed by anti-fibrosis
treatment with PZQ for several times. The inhibition of
transcriptional levels of profibrotic genes in HSCs by treatment
Figure 9. Anti-fibrosis treatment with prizaquantel inhibited expressions of profibrotic genes and a-SMA protein expression in
liver, but increased MMP9 mRNA expressions of mice 15 weeks post infection with Schistosoma japonicum. (A)a-SMA; (B)Col1a1;
(C)Col3a1; (D)TGF-b were reduced by anti-fibrosis treatment with high dose prizaquantel. (E)MMP9 levels in high dose group were increased about 10
fold compared with uninfected group, whereas (F) TIMP1 levels were decreased nearly to uninfected level. a-SMA protein expressions was assessed
by immunohistochemistry. (G) Representative images of immunohistochemistry by light microscope (6100). Gi, uninfected; Gii, infected; Giii, anti-
parasite; Giv, low dose; Gv, high dose. Arrows showed the positive staining. (H) a-SMA positive areas were measured by software IPP6.0. Expression of
IL-4 (I), IL-10 (J), IL-13(K) and IFN-c (L) were significantly reduced in high dose group compared respectively with infected, anti-parasite or low dose
group. (* p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0020247.g009
Figure 10. Treatment of prizaquantel for 3 days inhibited expressions of HSC profibrotic genes of mice 12 weeks post infection
with Schistosoma japonicum. Prizaquantel (250 mg/kg/day) was administrated to mice for 3 days. Primary HSCs were isolated and transcriptional
levels were assessed by Real Time PCR. Transcriptional level of (A) Col1a1, (B) a-SMA,(C) Col3a1, (D) TGF-b, (E) MMP9 and (F) TIMP1 in HSC of treated
mice were significantly reduced compared with untreated mice. (* p,0.05).
doi:10.1371/journal.pone.0020247.g010
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PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e20247with PZQ is probably part mechanism of its anti-fibrosis property.
Further molecular mechanism and clinical application of PZQ are
deserved to be investigated.
Supporting Information
Figure S1 PZQ treatment improved CCL4 -induced liver
fibrosis and serum transaminase. Liver sections of mice
from normal (A), CCL4 -induced liver fibrosis (B), and PZQ
treatment (C) groups were stained with Sirius Red, respectively.
Statistical analysis showed that PZQ treatment significantly
decreased collagen areas (D). PZQ treatment also decreased the
liver hydroxyproline content (E) and serum ALT/AST (F). (*,
p,0.05;**, p,0.01; ***, p,0.001).
(TIF)
Figure S2 PZQ treatment inhibited the expressions of
liver fibrosis associated genes in normal mice detected
by Real Time PCR. Results showed that PZQ treatment
significantly decreased the expression of Col1a1 (A), TGF-b (D)
and TIMP1 (F) (p,0.001), and the changes of Col3a1(B), a-
SMA(C), and MMP9(E) were not significant. (p.0.05).
(TIF)
Figure S3 Proliferation of spleen mononuclearcells
were not significantly changed by stimulation of SEA.
12 weeks post-infected schistosomiasis mice were first treated by
prizaquantel or control solution. Then spleen mononuclearcells
were isolated and stimulated by SEA or anti-CD3. The method of
incorporation of
3H-thymidine (TDR) was used to assess the
proliferation. (ns, no significance).
(TIF)
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